Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Foamix Pharmaceuticals Ltd. FOMX

Healthcare Biotechnology
Foamix Pharmaceuticals Ltd is a specialty pharmaceutical company. It is focused on the development and commercialization of foam based formulations and topical drugs for dermatological therapies mainly acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103, FDX104. The firm also has development and license agreements relating to its technology with... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:FOMX)

Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

GlobeNewswire March 9, 2020

Foamix Pharmaceuticals to Present at the Cowen and Company's 40th Annual Health Care Conference

GlobeNewswire February 25, 2020

Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea

GlobeNewswire February 18, 2020

Foamix and Menlo Announce Shareholder Approval of Proposed Merger

GlobeNewswire February 6, 2020

Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology

PR Newswire February 6, 2020

Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology

GlobeNewswire February 6, 2020

SHAREHOLDER ALERT: Monteverde & Associates PC is Investigating the Following Merger

ACCESSWIRE IA January 22, 2020

Foamix Announces OrbiMed's Support of Merger with Menlo Therapeutics

GlobeNewswire January 17, 2020

Foamix Announces AMZEEQ(TM) (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.

PR Newswire January 14, 2020
View More News ››

Opinion & Analysis (NDAQ:FOMX)

Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts

Streetwise Reports April 18, 2018
View More Opinion ››

Bullboard Posts (NDAQ:FOMX)

Be the first to post on this bullboard.

Nurcapital Corporation Ltd.

Nurcapital Corporation Ltd.

Nurcapital was incorporated under the Business Corporations Act (Ontario) on January 8, 2015. The Company is listed as a ...
View More »